AngioDynamics, Inc. 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for AngioDynamics, Inc., covering the three and six months ended November 30, 2010. The company designs, develops, and markets medical devices for minimally invasive procedures, primarily in peripheral vascular disease and oncology. Effective June 1, 2010, the company reorganized its reporting segments, combining Peripheral Vascular and Access into a single Vascular division, while maintaining a separate Oncology segment.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Nov 30, 2010 | 6 Months Ended Nov 30, 2010 |
|---|---|---|
| Net Sales | $53,372 | $104,879 |
| Gross Profit | $31,536 (59.1%) | $61,556 (58.7%) |
| Operating Income | $5,397 (10.1%) | $8,878 (8.5%) |
| Net Income | $3,279 | $5,167 |
| Diluted EPS | $0.13 | $0.21 |
| Cash & Marketable Securities | $110,603 (Balance Sheet) | $110,603 (Balance Sheet) |
| Total Debt | $6,680 (Current + Long-term) | $6,680 (Current + Long-term) |
| Operating Cash Flow | N/A | $11,626 |
Material Changes vs. Prior Period
- Revenue: Net sales for the three months ended Nov 30, 2010, were flat compared to the prior year ($53.4M vs. $53.5M). For the six-month period, sales increased 1% to $104.9M. Growth was driven by the Oncology segment (up 16% QoQ, 19% YoY), offset by declines in the Vascular segment (down 6% QoQ, 5% YoY) due to lower average selling prices and decreased unit sales of dialysis and angiographic products.
- Expenses: Research and Development (R&D) expenses increased 10% in the quarter and 9% for the six months, primarily due to clinical/regulatory costs for Oncology products and increased engineering headcount. General and Administrative (G&A) expenses rose 23% in the quarter, largely due to $772,000 in severance and restructuring costs.
- Profitability: Gross margins remained stable at 59.1% for the quarter but declined slightly to 58.7% for the six months compared to 59.6% in the prior year, reflecting pricing pressure in the Vascular division.
- Segment Performance: The Oncology segment operating income improved significantly to $629k (4.0% margin) from $118k (0.9% margin) in the prior quarter. The Vascular segment operating income decreased to $4.77M (12.7% margin) from $5.2M (13.1% margin).
Guidance, Outlook, and Risks
- Outlook: Management expects R&D expenditures to remain between 8% and 10% of net sales in fiscal 2011, driven by investments in NanoKnife technology. The company believes current cash and investment balances are sufficient for at least the next 12 months.
- Legal Proceedings: A patent infringement lawsuit against Vascular Solutions, Inc. was settled on December 21, 2010, with Vascular Solutions agreeing to a non-exclusive license. Litigation against biolitec regarding indemnification costs remains ongoing.
- Risks:
- Supply Chain: The company relies on a distribution agreement with Biocompatibles UK Limited for LC Beads (approx. 12% of net sales), which expires December 31, 2011. Failure to extend this agreement could adversely affect operations.
- Liquidity: The company holds $1.85 million in auction rate securities that have failed auctions, creating potential liquidity constraints if liquidation is required.
- Market Risk: Exposure to interest rate fluctuations is managed via interest rate swaps. Foreign currency exposure is currently limited (approx. 4% of sales).
Investor Verification Checklist
- Verify the status of the LC Bead distribution agreement with Biocompatibles UK Limited and the likelihood of renewal post-December 2011.
- Assess the liquidity risk associated with the $1.85 million in failed auction rate securities.
- Monitor the impact of the Vascular segment's declining average selling prices on future gross margins.
- Review the progress and regulatory approval status of the NanoKnife technology, which is a key driver of R&D spend and Oncology growth.
- Confirm the final financial impact of the settlement with Vascular Solutions, Inc.